Wadenswil, Switzerland, March 1, 2019 - Creoptix AG, a Switzerland-based company focused on next generation bioanalytical instruments, today proudly announced Gareth Jones joining the senior management team as VP Global Sales Operations
“We are very happy to have Gareth joining our company. He brings in vast experience in building up sales teams and establishing innovative new technologies in the analytical instrument business,“ said Matyas Vegh, CEO of Creoptix. “This is exactly what we need now after having generated first momentum with our technology.”
Gareth Jones joins Creoptix coming from TTP Labtech where he held the position of Director of European Sales & Support. Gareth brings over 25 years of commercial experience in the Life science sector, working with several small and large brands like Bio-Rad, Applied Biosystems, Cyntellect and GE Healthcare where he held sales operations or market development positions on European or global level.
“I am truly excited to be joining such a dynamic and innovative company like Creoptix. I believe Creoptix has the technology and capability to transform the way label free analysis is utilised within the drug discovery workflow and provide functionality that has, up until now, not been available with incumbent technology to date.
Creoptix is a private company headquartered in Wädenswil, near Zurich, Switzerland, and offices near Boston, USA. Creoptix focuses on next generation bioanalytical instruments for drug discovery and development as well as academic research. Based on its proprietary sensor and microfluidics technology, their Creoptix WAVE systems provide exceptionally high sensitivity and resolution in characterizing real-time interactions between small molecules, peptides, proteins and other molecules and in even crude samples like undiluted serum or plasma.